Hepatitis C Reinfection Isn't All That Uncommon in Patients with HIV

Article

Hepatitis C reinfection rates appear to be higher within certain populations.

infectious disease, hepatitis C, HCV

A new analysis suggests there’s a need for frequent testing after the hepatitis C virus has been cleared.

Data from three European countries and the United Kingdom indicate a rise in reinfection of acute hepatitis C among men with the human immunodeficiency virus (HIV) who have sex with men.

Moderate cure rates of acute hepatitis C have been reported in the last decade among men who have sex with men and also are infected with HIV. However, many who either clear the infection spontaneously or through treatment are later reinfected, researchers noted.

“With a high treatment uptake in this population even in the interferon era and with higher response rates to treatment in the acute phase of infection, reinfections are most likely occurring due to maintained risk behaviors,” the study authors wrote in the Journal of Hepatology.

Chronic infection of hepatitis C can lead to cirrhosis and other serious liver damage, including liver cancer. The authors pointed out that for patients with HIV, liver disease is a major cause of morbidity and mortality.

The research team examined more than a decade of data on patients with a documented cure of acute hepatitis C between 2002 and 2014. It included data from eight centers in Austria, France, Germany, and the UK, which are part of the NEAT consortium (European AIDS Treatment Network). Information gathered for the analysis included age, genotype, diagnosis date, as well as the date of cure and whether it was from treatment or spontaneous clearance of the hepatitis C virus and the date of last follow-up visit.

Among the 606 patients, 494 men (81.5%) had achieved sustained virologic response—indicating a cure—after being treated for the virus with pegylated interferon and ribavirin. One hundred and eleven men (18.3%) cleared the virus spontaneously. Documentation and details were lacking for the remaining one patient.

Results showed that 149 of the 606 men (24.6%) later presented with subsequent hepatitis C infection. In some cases, patients became reinfected for a second, third, or fourth time.

“Thirty out of 70 (43%) who cleared again or were successfully treated, presented with a second reinfection, five with a third, and one with a fourth reinfection,” wrote lead author, Patrick Ingiliz, MD, of the Center for Infectiology in Berlin, Germany, and colleagues. “The reinfection incidence was 7.3/100 person-years (95% CI 6.2—8.6).”

The authors found the incidence of reinfection “alarming” and noted that the study findings underline a need for intervention during follow-up care after a patient is cured of hepatitis C. They recommended prevention strategies such as testing for reinfection of hepatitis C every three to six months among this high-risk group.

“Prevention strategies — both treatment and behavioral – are needed to target high risk groups to reduce morbidity and treatment costs,” the team concluded. “Patients as well as clinicians have to be aware of the specific risk behavior in this setting and counseling should be accompanied by behavioral interventions to avoid reinfections.”

The study, “HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe” appears in the February issue of the Journal of Hepatology.

Related Coverage:

Hepatitis C Guideline Might Have Too Many Conflicts of Interest

VA Finds Success with Various Hepatitis C Regimens for Veterans

Hepatitis C Is No Match for Sorafenib-Treated Hepatocellular Carcinoma

Related Videos
Andrew Talal, MD | Credit: University at Buffalo
Andrew Talal, MD | Credit: University at Buffalo
Megan Rose Curtis, MD | Credit: Megan Rose Curtis on LinkedIn
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Wei Zhang, MD, PhD | Credit: Mass General Brigham
A Year of RSV Highs and Lows, with Tina Tan, MD
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis Cirrhosis than Men
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Nancy Reau, MD: Larsucosterol for Alcohol-Associated Hepatitis
© 2024 MJH Life Sciences

All rights reserved.